by Scott Burris, Stephen Koester
Author Archives: PLoS Medicine
by Unni Karunakara
by Kanna Hayashi, Will Small, Joanne Csete, Sattara Hattirat, Thomas Kerr Background Despite Thailand’s commitment to treating people who use drugs as “patients” not “criminals,” Thai authorities continue to emphasize criminal law enforcement for drug control. In 2003, Thailand’s drug war received international criticism due to extensive human rights violations. However, few studies have since investigated the impact of policing on drug-using populations. Therefore, we sought to examine experiences with policing among people who inject drugs (PWID) in Bangkok, Thailand, between 2008 and 2012. Methods and Findings Between July 2011 and June 2012, semi-structured, in-depth interviews were conducted with 42 community-recruited PWID participating in the Mitsampan Community Research Project in Bangkok
by Erik M. Volz, Edward Ionides, Ethan O. Romero-Severson, Mary-Grace Brandt, Eve Mokotoff, James S. Koopman Background Conventional epidemiological surveillance of infectious diseases is focused on characterization of incident infections and estimation of the number of prevalent infections.
by Timothy B. Hallett
by Daniele Fanelli
by The WorldWide Antimalarial Resistance Network (WWARN) DP Study Group Background Dihydroartemisinin-piperaquine (DP) is increasingly recommended for antimalarial treatment in many endemic countries; however, concerns have been raised over its potential under dosing in young children. We investigated the influence of different dosing schedules on DP’s clinical efficacy. Methods and Findings A systematic search of the literature was conducted to identify all studies published between 1960 and February 2013, in which patients were enrolled and treated with DP. Principal investigators were approached and invited to share individual patient data with the WorldWide Antimalarial Resistance Network (WWARN). Data were pooled using a standardised methodology
by Carolina Riveros, Agnes Dechartres, Elodie Perrodeau, Romana Haneef, Isabelle Boutron, Philippe Ravaud Background The US Food and Drug Administration Amendments Act requires results from clinical trials of Food and Drug Administration–approved drugs to be posted at ClinicalTrials.gov within 1 y after trial completion. We compared the timing and completeness of results of drug trials posted at ClinicalTrials.gov and published in journals. Methods and Findings We searched ClinicalTrials.gov on March 27, 2012, for randomized controlled trials of drugs with posted results. For a random sample of these trials, we searched PubMed for corresponding publications. Data were extracted independently from ClinicalTrials.gov and from the published articles for trials with results both posted and published.
by Alexander C. Tsai, David R. Bangsberg, Sheri D. Weiser
by James S. Yeh, Aaron S. Kesselheim
by Kate Mitchell, Mary Nell Wegner, Ana Langer, the PLOS Medicine Editors
by Quinn Grundy, Lisa Bero, Ruth Malone Background With increasing restrictions placed on physician–industry interactions, industry marketing may target other health professionals. Recent health policy developments confer even greater importance on the decision making of non-physician clinicians. The purpose of this systematic review is to examine the types and implications of non-physician clinician–industry interactions in clinical practice. Methods and Findings We searched MEDLINE and Web of Science from January 1, 1946, through June 24, 2013, according to PRISMA guidelines.
by Lone Simonsen, Peter Spreeuwenberg, Roger Lustig, Robert J. Taylor, Douglas M. Fleming, Madelon Kroneman, Maria D. Van Kerkhove, Anthony W. Mounts, W